Clinical TrialAug 3, 2026, 08:33 AM
Veru Provides Positive Updates on Enobosarm Obesity Clinical Trials
AI Summary
Veru Inc. announced it will host a conference call on August 10, 2026, to discuss its fiscal 2026 third-quarter financial results and provide a business update. The company also provided significant updates on its obesity program, including the full enrollment of its Phase 2b PLATEAU clinical study for enobosarm, with interim results expected in Q1 2027 and final data in Q4 2027. Additionally, the completed Phase 2b QUALITY clinical study showed positive results, demonstrating enobosarm's ability to preserve lean mass, improve physical function, and enhance fat loss.
Key Highlights
- Veru to host conference call on August 10, 2026, for Q3 2026 financial results.
- Phase 2b PLATEAU clinical study for enobosarm in obesity is fully enrolled.
- Interim analysis results for PLATEAU study expected in Q1 2027.
- Final topline data for PLATEAU study expected in Q4 2027.
- Phase 2b QUALITY clinical study completed with positive results.
- QUALITY study showed enobosarm preserved lean mass and physical function.
- QUALITY study demonstrated greater fat loss and prevented weight regain.
- Clinical supply agreement with Novo Nordisk for PLATEAU study in June 2026.
Price Impact
More from VERU